MBX Biosciences (NASDAQ: MBX) insider transactions
In the twelve months to 10 November 2026, executives and directors of MBX Biosciences reported 6 open-market sales of 71,584 shares ($2.8m) and 1 open-market purchase of 18,500 shares ($525,585), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 November 2026 | Azoulay Salomon | Chief Medical Officer | Open-market sale | −373 | $53.96 | 14,026 | Form 4 |
| 4 August 2026 | Azoulay Salomon | Chief Medical Officer | Open-market sale | −370 | $65.77 | 14,399 | Form 4 |
| 3 August 2026 | Hoerter Steven L. | President and CEO | Grant or award | +71,000 | — | 82,938 | Form 4 |
| 3 August 2026 | Smither John W | Chief Financial Officer | Grant or award | +28,000 | — | 28,000 | Form 4 |
| 8 May 2026 | Azoulay Salomon | Chief Medical Officer | Option exercise | +55,000 | $10.46 | 69,769 | Form 4 |
| 8 May 2026 | Azoulay Salomon | Chief Medical Officer | Open-market sale | −55,000 | $38.38 | 14,769 | Form 4 |
| 8 May 2026 | Azoulay Salomon | Chief Medical Officer | Option exercise | +15,003 | $16.00 | 29,772 | Form 4 |
| 8 May 2026 | Azoulay Salomon | Chief Medical Officer | Open-market sale | −15,003 | $38.30 | 14,769 | Form 4 |
| 6 May 2026 | Hawryluk P. Kent | President & CEO | Open-market sale | −607 | $29.54 | 727,667 | Form 4 |
| 6 May 2026 | Azoulay Salomon | Chief Medical Officer | Open-market sale | −231 | $29.54 | 14,769 | Form 4 |
| 1 May 2026 | Hoerter Steven L. | Director | Grant or award | +11,938 | — | 11,938 | Form 4 |
| 13 March 2026 | Hawryluk P. Kent | President & CEO | Open-market purchase | +18,500 | $28.41 | 486,777 | Form 4 |
| 26 February 2026 | Hawryluk P. Kent | President & CEO | Option exercise | +28,768 | $16.00 | 728,274 | Form 4 |
| 2 February 2026 | Hawryluk P. Kent | President & CEO | Grant or award | +35,250 | — | 699,506 | Form 4 |
| 2 February 2026 | Bartram Richard | Chief Financial Officer | Grant or award | +15,000 | — | 15,000 | Form 4 |
| 2 February 2026 | Azoulay Salomon | Chief Medical Officer | Grant or award | +15,000 | — | 15,000 | Form 4 |
| 24 October 2025 | Hawryluk P. Kent | President & CEO | Option exercise | +182,859 | $3.25 | 664,256 | Form 4 |
| 20 October 2025 | Hawryluk P. Kent | President & CEO | Open-market purchase | +20,000 | $13.64 | 468,277 | Form 4 |
| 17 October 2025 | Hoerter Steven L. | Director | Open-market purchase | +20,000 | $13.25 | 20,000 | Form 4 |
| 26 September 2025 | Fhmls X, L.p. | — | Open-market purchase | +666,666 | $18.00 | 5,219,440 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the MBX Biosciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.